Over 44,000 Pounds Of Shrimp Have Been Recalled Due To Listeria
Open any freezer and there's a good chance that you'll find a bag of frozen shrimp. This type of shellfish is delicious in so many dishes, from pasta to salads to tacos. But if you recently purchased a bag of frozen shrimp, you're going to want to check it before cooking. Bornstein Seafoods Inc., a Bellingham, Washington-based company, has recalled 44,550 pounds of shrimp due to possible listeria monocytogenes contamination, according to the FDA. The company says the listeria was found during a routine sampling, but no illnesses have been reported.
On June 10, the company announced the recall of Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat in 1 and 5-pound bags. According to the recall, the product was distributed to both retailers and wholesale distributors in Oregon, California, Washington, and British Columbia of Canada. But it's worth noting that the products could have been distributed beyond these states and provinces.
Listeria is a bacteria that can cause listeriosis, which can cause mild to severe symptoms. According to the FDA, mild cases can include symptoms like fever, nausea, vomiting, and diarrhea, while more severe cases can be life-threatening, especially for at-risk groups: those with weakened immune systems, adults over 65, pregnant people, and newborns.
To find out if you have recalled shrimp, you'll need to check the UPC codes and lot numbers, which can be found on the bag. A list of affected product can be found here.
If you do have recalled product, consumers are urged to return it to the place of purchase for a refund and to direct any questions to Andrew Bornstein at Andrew@bornstein.com.
You Might Also Like
Insanely Easy Weeknight Dinners To Try This Week
29 Insanely Delicious Vodka Cocktails
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
20 minutes ago
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease. Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older. Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults. More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when. Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk. The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC. Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine. As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations. meeting scheduled to be held between June 25 and June 27 Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine.
Yahoo
22 minutes ago
- Yahoo
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease. Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older. Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults. MORE: Despite 'game-changing' new RSV shots, uptake lagged among infants, adults: Experts More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when. Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk. The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC. Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine. MORE: Respiratory virus activity remains 'high' in US and will 'continue for several more weeks': CDC As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations. Instead, it appears Kennedy plans to have the new committee re-discuss the recommendations for RSV vaccination as well as discuss HPV and COVID vaccinations in their meeting scheduled to be held between June 25 and June 27 Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine. FDA expands approval of Moderna's RSV vaccine to some adults under age 60 originally appeared on
Yahoo
31 minutes ago
- Yahoo
FDA Announces Recall on Honey Bunches of Oats Cereal for Potential Metal Contamination
Post Consumer Brands, LLC, has issued a recall for select boxes of Honey Bunches of Oats because the cereal may be contaminated with foreign material, specifically metal. In total, more than 5,300 cases of Post Honey Bunches of Oats with Almonds are being recalled due to potential metal contamination. Post initially issued the recall on May 28, 2025, and the U.S. Food & Drug Administration (FDA) classified it as a 'Class II' recall, meaning eating the cereal 'may cause temporary or medically reversible adverse health consequences,' on June 12, 2025. The recalled Honey Bunches of Oats cereal was sold at stores in two states: California and Colorado. To determine if you have the contaminated cereal, look for the following information on the packaging: 48-ounce (3-pound) boxes of Post Honey Bunches of Oats with Almonds, Sweetened Cereal with Oats and Honey with two bags inside; UPC 8 84912-01428 3; "Best If Used By" Date APR0926 RCA and APR1026 RCA No other Honey Bunches of Oats cereals or Post products are impacted by this recall. Because the recall was announced in May, the impacted cereal is likely not available for purchase anymore. However, you should check the boxes in your pantry. If you have the recalled cereal, do not consume it. Instead, throw it away or return it to the original place of purchase for a refund or replacement. Additionally, if you discarded the box, but purchased Honey Bunches of Oats with Almonds cereal in California or Colorado and still have it in your home, you should not consume it out of an abundance of caution. At this time, the FDA hasn't reported any injuries caused by eating the contaminated cereal. Read the original article on ALLRECIPES
